Airsculpt Technologies, Inc. (AIRS)
NASDAQ:AIRS
Want to see AIRS full AI Analyst Report?
AIRS Stock Chart & Stats
$3.57
>-$0.01(-0.17%)
At close: 4:00 PM EST
$3.57
>-$0.01(-0.17%)
Day’s Range― - ―
52-Week Range$1.51 - $12.00
Previous CloseN/A
Volume69.34K
Average Volume (3M)1.05M
Market Cap
$196.82M
Enterprise Value$255.72M
Total Cash (Recent Filing)$8.45M
Total Debt (Recent Filing)$83.57M
Price to Earnings (P/E)23.3
Beta2.37
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding70,545,685
10 Day Avg. Volume629,231
30 Day Avg. Volume1,053,493
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.36
Price to Sales (P/S)0.79
P/FCF Ratio172.97
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.65
Enterprise Value/Ebitda55.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$153.25M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementCapital raise and subsequent debt paydown reduced leverage and improved covenant headroom, enhancing financial flexibility to support operational initiatives.
Demand Momentum From MarketingEnhanced sales and marketing efforts have increased leads and consults that are converting into cases, supporting improving same-store sales momentum toward a return to growth.
New Service ExpansionPilot program for skin removal surgeries can be scaled across the clinic footprint and surgeon network, creating a meaningful new revenue stream beyond existing procedures.
Bears Say
Commercial Execution RiskNeutral analyst stance highlights the need for more consistent commercial execution before the outlook can be upgraded, signaling execution risks that may temper investor confidence.
Financial Reporting And Leverage RiskPlanned extension to file the annual report combined with a notable level of debt relative to cash raises financial and disclosure risks that could weigh on the stock.
Volume And Profitability PressureDeclining case volumes and revenue that missed consensus indicate weakening demand and place pressure on adjusted profitability.
Airsculpt Technologies News
AIRS FAQ
What was Airsculpt Technologies, Inc.’s price range in the past 12 months?
Airsculpt Technologies, Inc. lowest stock price was $1.51 and its highest was $12.00 in the past 12 months.
What is Airsculpt Technologies, Inc.’s market cap?
Airsculpt Technologies, Inc.’s market cap is $196.82M.
When is Airsculpt Technologies, Inc.’s upcoming earnings report date?
Airsculpt Technologies, Inc.’s upcoming earnings report date is May 08, 2026 which is in 20 days.
How were Airsculpt Technologies, Inc.’s earnings last quarter?
Airsculpt Technologies, Inc. released its earnings results on Apr 06, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Airsculpt Technologies, Inc. overvalued?
According to Wall Street analysts Airsculpt Technologies, Inc.’s price is currently Overvalued.
Does Airsculpt Technologies, Inc. pay dividends?
Airsculpt Technologies, Inc. pays a Notavailable dividend of $0.41 which represents an annual dividend yield of N/A. See more information on Airsculpt Technologies, Inc. dividends here
What is Airsculpt Technologies, Inc.’s EPS estimate?
Airsculpt Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Airsculpt Technologies, Inc. have?
Airsculpt Technologies, Inc. has 70,545,685 shares outstanding.
What happened to Airsculpt Technologies, Inc.’s price movement after its last earnings report?
Airsculpt Technologies, Inc. reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -2.208%.
Which hedge fund is a major shareholder of Airsculpt Technologies, Inc.?
Currently, no hedge funds are holding shares in AIRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Airsculpt Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
AIRS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 880.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.81%
12-Months-Change
Fundamentals
Return on Equity
-13.79%
Trailing 12-Months
Asset Growth
-10.81%
Trailing 12-Months
Company Description
Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
AIRS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights a company in active turnaround: operational actions (cost savings, debt reduction, marketing enhancements) have produced Q4 margin expansion, improved same-store sales trends and early traction with new services (skin tightening and skin removal). However, material revenue declines in 2025, weaker full-year adjusted EBITDA versus 2024, a sharp drop in operating cash flow, modest year-end cash, supply risk for key equipment and a reporting control matter temper the progress. Management’s 2026 guidance is conservative and back‑end loaded, reflecting improving momentum but ongoing execution and liquidity risks.View all AIRS earnings summariesAIRS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AMN Healthcare Services
―
Community Health
―
Cross Country Healthcare
―
Healthcare Services
―
National Healthcare
―
Ownership Overview
Currently, No data available
---